Expression of the proliferating clinicopathological features in cell nuclear antigen and intracranial meningiomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Choong Hyun | - |
dc.contributor.author | Cheong, Jin Hwan | - |
dc.contributor.author | Bak, Koang Hum | - |
dc.contributor.author | Kim, Jae Min | - |
dc.contributor.author | Oh, Suck Jun | - |
dc.date.accessioned | 2023-07-05T03:55:20Z | - |
dc.date.available | 2023-07-05T03:55:20Z | - |
dc.date.created | 2021-10-29 | - |
dc.date.issued | 2001-05 | - |
dc.identifier.issn | 0967-5868 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186203 | - |
dc.description.abstract | PC10, a monoclonal antibody (mAb) to proliferating cell nuclear antigen (PCNA) is known to show immunoreactivity in paraffin-embedded specimens. The authors present the relation between PCNA expression and clinicopathological features in 38 intracranial meningiomas. PCNA scores were obtained by immunohistochemical staining of the paraffin-embedded sections using a streptoavidin-biotin immunoperoxidase method with PC10 mAb. Univariate analysis showed that high PC10 scores were associated with old age (greater than or equal to 50 years old), male, recurrent tumours, and meningothelial type. However, these high scores did not reach a statistical significance (P >0.05). PC10 scores of the basal meningioma tended to be higher than that of the hemispheric meningioma (P <0.05). The staining intensity of PCNA was also markedly increased in basal meningiomas. It is suggested that the proliferative potential is higher in basal meningiomas than in hemispheric meningiomas. Moreover, these results could reflect high recurrence and difficulty in management of the skull base meningiomas. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Expression of the proliferating clinicopathological features in cell nuclear antigen and intracranial meningiomas | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jae Min | - |
dc.identifier.doi | 10.1054/jocn.2001.0876 | - |
dc.identifier.scopusid | 2-s2.0-0034919628 | - |
dc.identifier.wosid | 000170422200011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL NEUROSCIENCE, v.8, pp.44 - 48 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL NEUROSCIENCE | - |
dc.citation.title | JOURNAL OF CLINICAL NEUROSCIENCE | - |
dc.citation.volume | 8 | - |
dc.citation.startPage | 44 | - |
dc.citation.endPage | 48 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY KI-67 | - |
dc.subject.keywordPlus | HUMAN-BRAIN TUMORS | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMICAL DETECTION | - |
dc.subject.keywordPlus | PROGESTERONE RECEPTORS | - |
dc.subject.keywordPlus | PARAFFIN SECTIONS | - |
dc.subject.keywordPlus | GROWTH FRACTION | - |
dc.subject.keywordPlus | CYCLIN PCNA | - |
dc.subject.keywordPlus | BROMODEOXYURIDINE | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | KINETICS | - |
dc.subject.keywordAuthor | meningioma | - |
dc.subject.keywordAuthor | PCNA | - |
dc.subject.keywordAuthor | clinicopathological feature | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0967586801908768?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.